The SPRINT-MS trial evaluated the novel drug ibudilast over 96 weeks in patients with primary and secondary progressive multiple sclerosis. The SPRINT-MS trial was a phase II clinical trial of ...
Two recent studies presented at the 4th Congress of the European Academy of Neurology examined the different effects and aspects of progressive multiple sclerosis. Two recent studies presented at the ...
Progressive Neurologic Changes in a Patient with Metastatic Non–Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? The following represents disclosure information provided by authors of ...
HealthDay on MSN
FDA approves Jascayd for progressive pulmonary fibrosis
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback